The Priority Review status is granted for drug submissions that aim to treat, prevent or diagnose serious, life-threatening or severely debilitating illnesses and conditions.
Price: 26.17, Change: +0.61, Percent Change: +2.33
|Consensus for Zumiez Q2 Earnings Raised but Full Yea...|
|Williams Sonoma's Q2, 2021, 2022 Full Year Earnings ...|
|Analysts' Ratchet Up 2020, 2021 Consensus Estimates ...|
|Q1, 2021, 2022 Earnings Estimates for Advanced Drain...|
|Q2 Projection for Westlake Chemical Increased but 20...|